Clinical trials: Retinopathy, Diabetic
Diabetic Retinopathy
A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.
The main objective is to evaluate ocular and systemic safety and tolerability of BI 1467335 as well as whether BI 1467335 monotherapy has a potential to improve retinal lesions in patients with moderately severe Non-proliferative…
- Trial name
- ROBIN (NCT03238963)
- Testing
- BI 1467335
- Where
- 35 sites in United States, Austria and 6 more
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Retinitis Pigmentosa (RP), Age Related Macular Degeneration
Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies
Summary of the Study This clinical trial evaluates a novel peptide-based therapy for treating retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy (DR).
- Conditions
- Retinitis Pigmentosa (RP), Age Related Macular Degeneration, Diabetic Retinopathy
- Trial name
- Retino (NCT06787482)
- Testing
- ACE Retino
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Ace Cells Lab Limited
Diabetic Macular Edema
Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema
This a non-interventional retrospective study on the efficiency and the tolerance of intravitreal injections of Aflibercept on vitrectomized eyes in the diabetic macular oedema
- Trial name
- MODEVA (NCT02874859)
- Where
- 8 sites in France
- Volunteers
- 49 people
- Sponsor
- Lille Catholic University
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)
This study is conducted to evaluate the safety of intravitreal THR-317 administered in combination with ranibizumab, and to assess the efficacy of the combination treatment in improving best-corrected visual acuity (BCVA) and…
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Macular Edema
- Trial name
- NCT03499223
- Testing
- Ranibizumab 0.5mg, THR-317 8mg
- Where
- 37 sites in Belgium, France and 5 more
- Volunteers
- 70 people
- Sponsor
- Oxurion
Diabetes Mellitus, Type 2
A Trial on Ophthalmologist-delivered Health Education on Top of Routine Community Care
Diabetic retinopathy affects over one third of all people with diabetes and is one of the leading causes of vision loss. The management of diabetes and its complications should include screening for diabetic retinopathy.
- Trial name
- NCT04490941
- Testing
- Ophthalmologist-delivered health education, Usual care
- Where
- China
- Volunteers
- 652 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Subfoveal Choroidal Thickness, Intravitreal
Subfoveal Choroidal Thickness and Visual Acuity After Intravitreal Injection of Ranibizumab in Diabetic Retinopathy
The aim of this study is to compare subfoveal choroidal thickness (SFCT) and the visual status before and after intravitreal injection of ranibizumab in diabetic macular edema (DME) with the use of 3D-OCT by enhanced depth…
- Conditions
- Subfoveal Choroidal Thickness, Intravitreal, Ranibizumab, Visual Acuity
- Trial name
- NCT06173245
- Testing
- Intravitreal injection of ranibizumab
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Egyptian Biomedical Research Network
Diabetic Retinopathy, Neurotrophic Keratitis
An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
Evaluate the association between level of decreased corneal sensitivity and diabetic retinopathy severity scale
- Trial name
- Assess (NCT05566717)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Medical Center Ophthalmology Associates
Proliferative Diabetic Retinopathy
The Individually Marked Panretinal lasEr phoTokoagUlation for Proliferative Diabetic Retinopathy Study - DETECT
The purpose of this study is to determine the threshold level of proliferative diabetic retinopathy progression and regression after standard panretinal photocoagulation.
- Trial name
- IMPETUS-D (NCT02157350)
- Testing
- Panretinal laser photocoagulation
- Where
- Denmark
- Volunteers
- 65 people
- Sponsor
- Odense University Hospital
Diabetic Retinopathy, Macular Oedema
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
This study evaluates a new investigational treatment regimen of three consecutive monthly doses of ranibizumab followed by an as-needed treatment regimen, with monthly follow-up for the first three months then two-monthly…
- Trial name
- RELIGHT (NCT01257815)
- Testing
- Ranibizumab
- Where
- 15 sites in United Kingdom
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Diabetic Retinopathy
Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab
Purpose: To evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure (IOP) variations after intravitreal bevacizumab injection (IVBV).
- Conditions
- Macular Edema, Diabetic Retinopathy, Macular Degeneration
- Trial name
- NCT00804921
- Testing
- bevacizumab, anterior chamber paracentesis, acetazolamide
- Where
- Brazil
- Sponsor
- University of Sao Paulo
Non Proliferative Diabetic Retinopathy
Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR
It is estimated that there are about 600 million diabetes mellitus (DM) patients all over the world until 2040，and almost 50% of whom have some degree of diabetic retinopathy (DR) at any given time.
- Trial name
- NCT04103671
- Testing
- Prompt panretinal photocoagulation, 25G Pars-plana vitrectomy
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Diabetic Proliferative Retinopathy, Vascular Vein Oclussion
Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment
Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG). Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion…
- Conditions
- Diabetic Proliferative Retinopathy, Vascular Vein Oclussion, Choroidal Neovascularization
- Trial name
- NCT00417833
- Testing
- Intravitreal Bevacizumab
- Sponsor
- Asociación para Evitar la Ceguera en México
Diabetic Macular Edema of Both Eyes (Diagnosis), Diabetic Retinopathy Visually Threatening
Shanghai Cohort Study of Diabetic Eye Disease
To describe the design, methodology and baseline characteristics of the Shanghai Cohort study of Diabetic Eye disease (SCODE) study, a community-based study to determine the prevalence and impact of diabetic eye disease…
- Trial name
- SCODE (NCT03665090)
- Testing
- Diabetic eye disease screening
- Volunteers
- 8,000 people
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Diabetic Retinopathy Patients After Vitrectomy
Comparison of the Visual Quality of Traditional Ultrasound Biometrics and Lenstar on the Cataract After Pars Plana Vitrectomy
Comparison of the visual quality of traditional ultrasound biometrics and lenstar on the cataract patients with diabetic retinopathy after vitrectomy in the 3 months later.To evaluate the clinical value of lenstar in…
- Trial name
- PPV (NCT03485586)
- Testing
- Traditional ultrasound biometrics, Lenstar
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Bojie Hu
Proliferative Diabetic Retinopathy
Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy.
The used of reduced fluence parameters for panretinal photocoagulation decreases pain as perceived by the patient, compared to traditional parameters.
- Trial name
- NCT00802269
- Testing
- Retinal laser photocoagulation
- Where
- Mexico
- Volunteers
- 25 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Retinal Disease
Changes in Retinal Nerve Fiber Layer Thickness Detected by OCT in Diabetic Retinopathy After Panretinal Photocoagulation
Panretinal photocoagulation reduces the risk of visual loss by 50% in patients with diabetic retinopathy. It is recognized that laser expansion into the retina may be associated with photoreceptor loss, retinal pigment epithelial…
- Trial name
- NCT03786146
- Volunteers
- 30 people
- Sponsor
- Assiut University
Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression
Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus (DM), while proliferative diabetic retinopathy (PDR) is the principal cause of severe visual loss in patients with diabetes.
- Conditions
- Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression, Diabetic Retinopathy
- Trial name
- PROPER (NCT04674254)
- Testing
- Bevacizumab Injection, Targeted retinal photocoagulation, Standard pan-retinal photocoagulation
- Where
- Egypt
- Volunteers
- 43 people
- Sponsor
- Cairo University
Diabetic Retinopathy, Diabetic Macular Edema
Predicting Diabetic Retinopathy From Risk Factor Data and Digital Retinal Images
The objective of this study is to compare the results of a deep learning approach to diabetic retinopathy assessment with results from (1) an in-person examination with an ophthalmologist, and (2) the assessments of optometrists…
- Trial name
- NCT03694145
- Testing
- In-Person Eye Examination
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Charles Drew University of Medicine and Science
Diabetic Macular Edema
Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)
The objective of this trial is to assess the safety, efficacy, and tolerability of RZ402 in patients with Diabetic Macular Edema.
- Trial name
- NCT05712720
- Testing
- Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402
- Where
- 32 sites in United States
- Volunteers
- 94 people
- Sponsor
- Rezolute
Diabetic Retinopathy, Clinically Significant Macular Edema
Reduction of Foveal Sensitivity in Eyes With Diabetic Macular Edema
Clinically significant macular edema (CSME) is a thickening of the macula associated with the risk of visual loss, which increases its centre is involved.
- Trial name
- NCT01824862
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Hospital Juarez de Mexico
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.